How pharma companies can communicate effectively in today’s evolving marketplace and why it is the right time to embrace our humanity when engaging various stakeholders along the product, patient, and reimbursement/coverage journeys.
Tag Archive for: reimbursement
The pharmacy benefit management subsidiary of CVS Health is favoring Humira’s biosimilars for its major formularies, with AbbVie’s branded product to be nixed on April 1, 2024.
Part V: Cost pressures, increasing value while improving health outcomes, and leveraging real-world evidence are top of mind.
In May 2023, the menopause drug received FDA approval for treating moderate to severe symptoms. Astellas said in Thursday’s announcement that the late-stage results “will support health technology assessment and reimbursement dossiers throughout Europe.”
Market access has been and continues to be an important process, and as of late many agencies have been boosting their capabilities in this area. We recently caught up with Ellen Cappellino, the new executive director of value, access, and reimbursement at Klick Health and the agency’s chief medical officer, Holly Henry, to discuss current market access issues and its future.
The former AstraZeneca and Vertex Pharmaceuticals executive bolsters the agency’s value, access, and reimbursement practice.
Rising to meet the dynamic demands of the healthcare sector, The Bloc Value Builders, a Bloc Agency, has strategically expanded its footprint in market access by introducing a consultancy division. The Value Builders announced this groundbreaking initiative is further strengthened by the appointment of Carolyn Atchison. She will serve as the senior vice president of market access consulting, boasting more than 20 years of expertise at industry front-runners like Amgen and Acadia Pharmaceuticals.
BioMarin Pharmaceutical Inc. announced that an individual in Germany with severe hemophilia A was treated with Roctavian (valoctocogene roxaparvovec-rvox), marking the first time that the gene therapy has been given commercially in Europe.
Market access in oncology impacts HCP willingness to write the Rx, ability for the office staff to facilitate clearance of the prior authorizations to access the Rx, and patient affordability to start and stay on therapy over time. Particularly for patients and caregivers who are told they must enter battle with the diagnosis of a solid or squamous tumor type — avoiding delays to the initiation of therapy is vital to helping improve the chances of survival with a meaningful quality of life.
The U.S. Medicare health plan on Thursday offered details of plans to collect patient data as a condition for reimbursement for Eisai Co. Ltd. and Biogen Inc.’s new Alzheimer’s drug Leqembi, should it win traditional U.S. approval as expected by July 6.